Table 4.
Correlation of MRPL13 Expression* with Clinicopathological Characteristics of Breast Cancer, Based on the Logistic Regression Analysis
| Clinical Characteristics | Total (N) | Odds Ratio in MRPL13 Expression | P-value |
|---|---|---|---|
| Age (≤50 vs >50) | 1097 | 1.13 (0.97–1.99) | 0.231 |
| Stage (I+II vs III+IV) | 1073 | 0.72 (0.46–1.22) | 0.003 |
| T (T1+2 vs T3+4) | 1094 | 0.82 (0.51–1.49) | 0.026 |
| N (N0 vs N1+2+3) | 1077 | 0.95 (0.67–1.55) | 0.412 |
| M (M0 vs M1) | 934 | 0.36 (0.28–0.87) | <0.001 |
| Histological type (IDC vs ILC) | 987 | 1.65 (1.09–2.87) | 0.035 |
| ER status (negative vs positive) | 984 | 1.39 (0.97–2.44) | 0.006 |
| PR status (negative vs positive) | 981 | 1.41 (1.01–2.89) | 0.027 |
| Her-2 status (negative vs positive) | 687 | 0.91 (0.67–1.83) | 0.107 |
| TNBC (non-TNBC vs TNBC) | 719 | 0.71 (0.44–1.30) | 0.002 |
Note: *Categorical dependent variable, greater or less than the median MRPL13 expression level.
Abbreviations: IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma.